Kura Oncology, Inc. (NASDAQ:KURA - Get Free Report) CEO Troy Edward Wilson acquired 100,000 shares of the business's stock in a transaction that occurred on Monday, August 17th. The stock was purchased at an average price of $11.12 per share, for a total transaction of $1,112,000.00. Following the completion of the transaction, the chief executive officer owned 379,194 shares in the company, valued at $4,216,637.28. The trade was a 35.82% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
Kura Oncology Trading Up 3.9%
Kura Oncology stock opened at $11.28 on Tuesday. Kura Oncology, Inc. has a 52-week low of $6.95 and a 52-week high of $12.49. The company has a quick ratio of 4.71, a current ratio of 4.73 and a debt-to-equity ratio of 0.12. The firm has a market capitalization of $1.00 billion, a price-to-earnings ratio of -3.35 and a beta of 0.38. The firm has a 50-day moving average price of $10.27 and a two-hundred day moving average price of $9.36.
Kura Oncology (NASDAQ:KURA - Get Free Report) last announced its quarterly earnings results on Wednesday, August 12th. The company reported ($0.77) EPS for the quarter, beating the consensus estimate of ($0.88) by $0.11. The company had revenue of $20.87 million for the quarter, compared to analyst estimates of $20.16 million. Kura Oncology had a negative net margin of 384.30% and a negative return on equity of 207.18%. Sell-side analysts expect that Kura Oncology, Inc. will post -3.3 earnings per share for the current year.
Analysts Set New Price Targets
KURA has been the topic of several analyst reports. Sanford C. Bernstein set a $24.00 target price on Kura Oncology in a research report on Monday, June 15th. Citigroup reiterated a "market outperform" rating on shares of Kura Oncology in a research report on Thursday, May 28th. Weiss Ratings reissued a "sell (d-)" rating on shares of Kura Oncology in a research note on Friday, July 17th. Cantor Fitzgerald reissued an "overweight" rating on shares of Kura Oncology in a report on Thursday, June 4th. Finally, Wedbush lifted their price objective on shares of Kura Oncology from $36.00 to $38.00 and gave the company an "outperform" rating in a research note on Thursday, August 13th. Ten equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Kura Oncology has a consensus rating of "Moderate Buy" and a consensus target price of $25.62.
Get Our Latest Stock Analysis on KURA
Institutional Investors Weigh In On Kura Oncology
Several hedge funds and other institutional investors have recently added to or reduced their stakes in KURA. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Kura Oncology by 6.3% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 50,008 shares of the company's stock worth $333,000 after purchasing an additional 2,977 shares during the period. Strs Ohio acquired a new stake in shares of Kura Oncology in the first quarter valued at $143,000. Legal & General Group Plc lifted its holdings in shares of Kura Oncology by 35.1% in the second quarter. Legal & General Group Plc now owns 72,910 shares of the company's stock valued at $421,000 after buying an additional 18,930 shares during the period. Rhumbline Advisers boosted its stake in Kura Oncology by 13.0% during the second quarter. Rhumbline Advisers now owns 118,896 shares of the company's stock valued at $686,000 after buying an additional 13,690 shares in the last quarter. Finally, American Century Companies Inc. boosted its stake in Kura Oncology by 244.5% during the second quarter. American Century Companies Inc. now owns 232,752 shares of the company's stock valued at $1,343,000 after buying an additional 165,189 shares in the last quarter.
Kura Oncology Company Profile
(
Get Free Report)
Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura's research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.
The company's lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
